Literature DB >> 29954253

Two Cases and a Review of Graft-Versus-Host Disease and the Role of Hepatitis C Treatment in Liver Transplant Patients.

Sonali D Advani1, Anoma Nellore2, Giorgos Hadjivassiliou2, Devin E Eckhoff3, Donna Salzman4, Daniel Lavie5, Peter Pavlidakey6, John W Baddley2,7.   

Abstract

Graft-versus-host disease (GvHD) is a rare but fatal complication after solid organ transplantation arising in 1% to 2% of cases. We report 2 cases of GvHD after orthotopic liver transplantation. Both patients had a history of hepatitis C virus (HCV) infection prior to transplantation. Both cases presented between 1 and 4 months after transplantation with rash, pancytopenia, and/or diarrhea. Our second case also developed oral and ocular manifestations after liver transplantation, which are more commonly described after stem cell transplantation. Diagnosis in both cases was made by clinical presentation in conjunction with histopathology and flow cytometry. Both patients were treated by increasing immunosuppression with tacrolimus and high-dose steroids. Response to treatment differed based on the degree of pancytopenia. Our case report is distinguished by several factors such as the context of GvHD presentation and the role of HCV treatment. Diagnosis of GvHD is difficult and often delayed due to nonspecific presentation that overlaps with other conditions. Furthermore, the relation between HCV treatment and potential initiation of GvHD in solid organ transplant patients is unclear.

Entities:  

Keywords:  GvHD; hepatitis C treatment; immune system diseases; liver transplant; therapeutics

Mesh:

Substances:

Year:  2018        PMID: 29954253     DOI: 10.1177/1526924818781558

Source DB:  PubMed          Journal:  Prog Transplant        ISSN: 1526-9248            Impact factor:   1.187


  1 in total

1.  Acute graft-versus-host disease after liver transplantation in a close contact with COVID-19: A case report.

Authors:  Lu Wang; Bo Yang; Lai Wei; Dong Chen; Yuanyuan Zhao; Zhishui Chen
Journal:  Transpl Immunol       Date:  2021-06-30       Impact factor: 1.708

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.